The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?

Issue title: Alzheimer’s Disease: New Beginnings

Guest editors: G. Perry, J. Avila, P.I. Moreira, A.A. Sorensen and M. Tabaton

Article type: Review Article

Authors: Bhat, Ratan V.^a | Andersson, Ulf^b | Andersson, Shalini^c | Knerr, Laurent^d | Bauer, Udo^a | Sundgren-Andersson, Anna K.^e

Affiliations: [a] Strategy and External Innovation, Cardiovascular, Renal and Metabolism Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden | [b] Drug Safety and Metabolism, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden | [c] Drug Metabolism and Pharmacokinetics, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden | [d] Medicinal Chemistry Cardiovascular and Metabolic Disease, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden | [e] Cardiovascular, Renal and Metabolic disease, Global Medicines Development, AstraZeneca Gaithersburg, MD, USA

Correspondence: [*] Correspondence to: Ratan Bhat, PhD, AstraZeneca R&D Gothenburg, Innovative Medicines and Early Development Biotech Unit, Cardiovascular and Metabolic Disease, Pepparedsleden 1, SE-431 83 Mölndal, Sweden. Tel.: +46705 62 87 27; E-mail: Ratan.Bhat@astrazeneca.com.

Abstract: Spanning over three decades of extensive drug discovery research, the efforts to develop a potent and selective GSK3 inhibitor as a therapeutic for the treatment of type 2 diabetes, Alzheimer’s disease (AD), bipolar disorders and cancer have been futile. Since its initial discovery in 1980 and subsequent decades of research, one cannot underscore the importance of the target and the promise of a game changing disease modifier. Several pharmaceutical companies, biotech companies, and academic institutions raged in a quest to unravel the biology and discover potent and selective GSK3 inhibitors, some of which went through clinical trials. However, the conundrum of what happened to the fate of the AstraZeneca’s GSK3 inhibitors and the undertaking to find a therapeutic that could control glycogen metabolism and aberrant tau hyperphosphorylation in the brain, and rescue synaptic dysfunction has largely been untold. AstraZeneca was in the forefront of GSK3 drug discovery research with six GSK3 drug candidates, one of which progressed up to Phase II clinical trials in the quest to untangle the tau hypothesis for AD. Analysis of key toxicity issues, serendipitous findings and efficacy, and biomarker considerations in relation to safety margins have limited the potential of small molecule therapeutics as a way forward. To guide future innovation of this important target, we reveal the roller coaster journey comprising of two decades of preclinical and clinical GSK3 drug discovery at AstraZeneca; the understanding of which could lead to improved GSK3 therapies for disease. These learnings in combination with advances in achieving kinase selectivity, different modes of action as well as the recent discovery of novel conjugated peptide technology targeting specific tissues have potentially provided a venue for scientific innovation and a new beginning for GSK3 drug discovery.

Keywords: Alzheimer’s disease, drug targeting, tau

DOI: 10.3233/JAD-179934

Journal: Journal of Alzheimer's Disease, vol. 64, no. s1, pp. S547-S554, 2018